121 related articles for article (PubMed ID: 38728186)
41. Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker.
Gleason CE; Norton D; Anderson ED; Wahoske M; Washington DT; Umucu E; Koscik RL; Dowling NM; Johnson SC; Carlsson CM; Asthana S;
J Alzheimers Dis; 2018; 61(1):79-89. PubMed ID: 29125485
[TBL] [Abstract][Full Text] [Related]
42. Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease.
Almeida RP; Schultz SA; Austin BP; Boots EA; Dowling NM; Gleason CE; Bendlin BB; Sager MA; Hermann BP; Zetterberg H; Carlsson CM; Johnson SC; Asthana S; Okonkwo OC
JAMA Neurol; 2015 Jun; 72(6):699-706. PubMed ID: 25893879
[TBL] [Abstract][Full Text] [Related]
43. CSF lactate levels, τ proteins, cognitive decline: a dynamic relationship in Alzheimer's disease.
Liguori C; Stefani A; Sancesario G; Sancesario GM; Marciani MG; Pierantozzi M
J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):655-9. PubMed ID: 25121572
[TBL] [Abstract][Full Text] [Related]
44. Associations of Neuropsychiatric Features with Cerebrospinal Fluid Biomarkers of Amyloidogenesis and Neurodegeneration in Dementia with Lewy Bodies Compared with Alzheimer's Disease and Cognitively Healthy People.
de Oliveira FF; Miraldo MC; de Castro-Neto EF; de Almeida SS; Matas SLA; Bertolucci PHF; Naffah-Mazzacoratti MDG
J Alzheimers Dis; 2021; 81(3):1295-1309. PubMed ID: 33935098
[TBL] [Abstract][Full Text] [Related]
45. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment.
Baldeiras I; Santana I; Leitão MJ; Gens H; Pascoal R; Tábuas-Pereira M; Beato-Coelho J; Duro D; Almeida MR; Oliveira CR
Alzheimers Res Ther; 2018 Mar; 10(1):33. PubMed ID: 29558986
[TBL] [Abstract][Full Text] [Related]
46. Baseline Results: The Association Between Cardiovascular Risk and Preclinical Alzheimer's Disease Pathology (ASCEND) Study.
Kumar VV; Huang H; Zhao L; Verble DD; Nutaitis A; Tharwani SD; Brown AL; Zetterberg H; Hu W; Shin R; Kehoe PG; Quyyumi A; Nocera J; Kippels A; Wharton W
J Alzheimers Dis; 2020; 75(1):109-117. PubMed ID: 32280088
[TBL] [Abstract][Full Text] [Related]
47. Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data.
Guhra M; Thomas C; Boedeker S; Kreisel S; Driessen M; Beblo T; Ohrmann P; Toepper M
Exp Gerontol; 2016 Jan; 73():107-13. PubMed ID: 26585048
[TBL] [Abstract][Full Text] [Related]
48. Heterogeneity of Cerebrospinal Fluid Biomarkers Profiles in Individuals with Distinct Levels of Cognitive Decline: A Cross-Sectional Study.
Pais M; Loureiro J; do Vale V; Radanovic M; Talib L; Stella F; Forlenza O
J Alzheimers Dis; 2021; 81(3):949-962. PubMed ID: 33843685
[TBL] [Abstract][Full Text] [Related]
49. Late-Life Obesity Associated with Tau Pathology in Cognitively Normal Individuals: The CABLE Study.
Zhang XX; Ma YH; Hu HY; Ma LZ; Tan L; Yu JT
J Alzheimers Dis; 2022; 85(2):877-887. PubMed ID: 34897094
[TBL] [Abstract][Full Text] [Related]
50. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
51. Serum Uric Acid May Aggravate Alzheimer's Disease Risk by Affecting Amyloidosis in Cognitively Intact Older Adults: The CABLE Study.
Li LL; Ma YH; Bi YL; Sun FR; Hu H; Hou XH; Xu W; Shen XN; Dong Q; Tan L; Yang JL; Yu JT
J Alzheimers Dis; 2021; 81(1):389-401. PubMed ID: 33814427
[TBL] [Abstract][Full Text] [Related]
52. Sleep Characteristics and Cognitive Function in Older Adults Without Dementia: The CABLE Study.
Fu Y; Wang ZT; Qu Y; Wang XT; Ma YH; Bi YL; Dong Q; Tan L; Yu JT
J Alzheimers Dis; 2021; 84(3):1029-1038. PubMed ID: 34602483
[TBL] [Abstract][Full Text] [Related]
53. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
54. NEURONORMA Cognitive Battery Associations with Cerebrospinal Fluid Amyloid-β and Tau Levels in the Continuum of Alzheimer's Disease.
García-Escobar G; Puig-Pijoan A; Puente-Periz V; Fernández-Lebrero A; María Manero R; Navalpotro-Gómez I; Suárez-Calvet M; Grau-Rivera O; Contador-Muñana J; Cascales-Lahoz D; Duran-Jordà X; Boltes N; Pont-Sunyer MC; Ortiz-Gil J; Carrillo-Molina S; López-Villegas MD; Abellán-Vidal MT; Martínez-Casamitjana MI; Hernández-Sánchez JJ; Padrós-Fluvià A; Peña-Casanova J; Sánchez-Benavides G
J Alzheimers Dis; 2023; 92(4):1303-1321. PubMed ID: 37038810
[TBL] [Abstract][Full Text] [Related]
55. Elevated Inflammatory Markers and Arterial Stiffening Exacerbate Tau but Not Amyloid Pathology in Older Adults with Mild Cognitive Impairment.
Clark AL; Weigand AJ; Thomas KR; Solders SK; Delano-Wood L; Bondi MW; Bernier RA; Sundermann EE; Banks SJ; Bangen KJ;
J Alzheimers Dis; 2021; 80(4):1451-1463. PubMed ID: 33682714
[TBL] [Abstract][Full Text] [Related]
56. Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease.
Okonkwo OC; Alosco ML; Griffith HR; Mielke MM; Shaw LM; Trojanowski JQ; Tremont G;
Arch Neurol; 2010 Jun; 67(6):688-96. PubMed ID: 20558388
[TBL] [Abstract][Full Text] [Related]
57. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
[TBL] [Abstract][Full Text] [Related]
58. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
[TBL] [Abstract][Full Text] [Related]
59. Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies.
van Steenoven I; van der Flier WM; Scheltens P; Teunissen CE; Lemstra AW
Alzheimers Res Ther; 2019 Oct; 11(1):83. PubMed ID: 31601267
[TBL] [Abstract][Full Text] [Related]
60. Associations between multimorbidity burden and Alzheimer's pathology in older adults without dementia: the CABLE study.
Aerqin Q; Chen XT; Ou YN; Ma YH; Zhang YR; Hu HY; Tan L; Yu JT
Neurobiol Aging; 2024 Feb; 134():1-8. PubMed ID: 37950963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
